CN104224727B - 一种中药微丸的制备方法 - Google Patents
一种中药微丸的制备方法 Download PDFInfo
- Publication number
- CN104224727B CN104224727B CN201410270961.4A CN201410270961A CN104224727B CN 104224727 B CN104224727 B CN 104224727B CN 201410270961 A CN201410270961 A CN 201410270961A CN 104224727 B CN104224727 B CN 104224727B
- Authority
- CN
- China
- Prior art keywords
- extract
- base ball
- temperature
- charge
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 132
- 238000002360 preparation method Methods 0.000 title claims abstract description 54
- 239000008188 pellet Substances 0.000 title claims abstract description 39
- 239000000284 extract Substances 0.000 claims abstract description 136
- 229940079593 drug Drugs 0.000 claims abstract description 45
- 239000002245 particle Substances 0.000 claims abstract description 29
- 240000007164 Salvia officinalis Species 0.000 claims description 126
- 235000017276 Salvia Nutrition 0.000 claims description 119
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 77
- 239000007788 liquid Substances 0.000 claims description 76
- 239000011248 coating agent Substances 0.000 claims description 54
- 238000000576 coating method Methods 0.000 claims description 54
- 239000002253 acid Substances 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 33
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 claims description 32
- 239000007921 spray Substances 0.000 claims description 32
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N tanshinone IIA Natural products C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 claims description 29
- GVKKJJOMQCNPGB-JTQLQIEISA-N Cryptotanshinone Chemical compound O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1[C@@H](C)CO2 GVKKJJOMQCNPGB-JTQLQIEISA-N 0.000 claims description 20
- GVKKJJOMQCNPGB-UHFFFAOYSA-N Cryptotanshinone Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)CO2 GVKKJJOMQCNPGB-UHFFFAOYSA-N 0.000 claims description 20
- 238000010348 incorporation Methods 0.000 claims description 20
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 claims description 19
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 claims description 19
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 claims description 19
- HYXITZLLTYIPOF-UHFFFAOYSA-N Tanshinone II Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)=CO2 HYXITZLLTYIPOF-UHFFFAOYSA-N 0.000 claims description 19
- AZEZEAABTDXEHR-UHFFFAOYSA-M sodium;1,6,6-trimethyl-10,11-dioxo-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-2-sulfonate Chemical compound [Na+].C12=CC=C(C(CCC3)(C)C)C3=C2C(=O)C(=O)C2=C1OC(S([O-])(=O)=O)=C2C AZEZEAABTDXEHR-UHFFFAOYSA-M 0.000 claims description 19
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims description 18
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims description 17
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 claims description 15
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 claims description 15
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 claims description 15
- 238000005507 spraying Methods 0.000 claims description 15
- 229920002472 Starch Polymers 0.000 claims description 13
- 238000001802 infusion Methods 0.000 claims description 13
- 235000005412 red sage Nutrition 0.000 claims description 13
- 239000008107 starch Substances 0.000 claims description 13
- 235000019698 starch Nutrition 0.000 claims description 13
- 238000005243 fluidization Methods 0.000 claims description 12
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 9
- 229960003511 macrogol Drugs 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 238000004806 packaging method and process Methods 0.000 claims description 2
- 241001072909 Salvia Species 0.000 claims 6
- 150000002576 ketones Chemical class 0.000 claims 2
- 238000010521 absorption reaction Methods 0.000 abstract description 6
- 230000002567 autonomic effect Effects 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 96
- 239000006228 supernatant Substances 0.000 description 48
- 239000000243 solution Substances 0.000 description 35
- 239000006286 aqueous extract Substances 0.000 description 31
- 239000002775 capsule Substances 0.000 description 30
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 28
- 239000006187 pill Substances 0.000 description 26
- 241000252212 Danio rerio Species 0.000 description 23
- 238000003756 stirring Methods 0.000 description 23
- 239000008280 blood Substances 0.000 description 22
- 210000004369 blood Anatomy 0.000 description 22
- 239000000463 material Substances 0.000 description 22
- 230000004089 microcirculation Effects 0.000 description 22
- 239000000843 powder Substances 0.000 description 20
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- 238000000605 extraction Methods 0.000 description 18
- 238000003809 water extraction Methods 0.000 description 16
- 238000012360 testing method Methods 0.000 description 15
- 239000003643 water by type Substances 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000008213 purified water Substances 0.000 description 12
- 238000001914 filtration Methods 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 238000012216 screening Methods 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 9
- 150000002632 lipids Chemical class 0.000 description 9
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 9
- 235000021286 stilbenes Nutrition 0.000 description 9
- 241000544602 Ageratum Species 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 238000000889 atomisation Methods 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 238000004140 cleaning Methods 0.000 description 8
- 239000012141 concentrate Substances 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 238000010992 reflux Methods 0.000 description 8
- 238000009826 distribution Methods 0.000 description 7
- 239000000543 intermediate Substances 0.000 description 7
- 210000001161 mammalian embryo Anatomy 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000013558 reference substance Substances 0.000 description 7
- 241001088162 Primula auricula Species 0.000 description 6
- 235000006894 Primula auricula Nutrition 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 239000004744 fabric Substances 0.000 description 6
- 238000011049 filling Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 210000003462 vein Anatomy 0.000 description 6
- 241000202726 Bupleurum Species 0.000 description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 5
- 229930183118 Tanshinone Natural products 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000005520 cutting process Methods 0.000 description 5
- 239000009524 danshen dripping Substances 0.000 description 5
- 238000007599 discharging Methods 0.000 description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 5
- 239000008108 microcrystalline cellulose Substances 0.000 description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 description 5
- 241000251468 Actinopterygii Species 0.000 description 4
- 241000208340 Araliaceae Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 4
- 235000003140 Panax quinquefolius Nutrition 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 230000000857 drug effect Effects 0.000 description 4
- 235000008434 ginseng Nutrition 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000004445 quantitative analysis Methods 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 229960004793 sucrose Drugs 0.000 description 3
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 206010048865 Hypoacusis Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000010812 external standard method Methods 0.000 description 2
- 230000004720 fertilization Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 230000000366 juvenile effect Effects 0.000 description 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
- 229960004844 lovastatin Drugs 0.000 description 2
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 2
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 150000007965 phenolic acids Chemical class 0.000 description 2
- 239000011505 plaster Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000007430 reference method Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- 108700015822 zebrafish fat1a Proteins 0.000 description 2
- ATADHKWKHYVBTJ-FVGYRXGTSA-N (R)-adrenaline hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=C(O)C(O)=C1 ATADHKWKHYVBTJ-FVGYRXGTSA-N 0.000 description 1
- 241001529821 Agastache Species 0.000 description 1
- 240000008100 Brassica rapa Species 0.000 description 1
- 235000011292 Brassica rapa Nutrition 0.000 description 1
- YTBSYETUWUMLBZ-QWWZWVQMSA-N D-threose Chemical compound OC[C@@H](O)[C@H](O)C=O YTBSYETUWUMLBZ-QWWZWVQMSA-N 0.000 description 1
- 206010016825 Flushing Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- -1 Polyphenol Acids Chemical class 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 235000021384 green leafy vegetables Nutrition 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229930189533 tanshinol Natural products 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940072040 tricaine Drugs 0.000 description 1
- FQZJYWMRQDKBQN-UHFFFAOYSA-N tricaine methanesulfonate Chemical compound CS([O-])(=O)=O.CCOC(=O)C1=CC=CC([NH3+])=C1 FQZJYWMRQDKBQN-UHFFFAOYSA-N 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 150000003673 urethanes Chemical class 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
药典筛 | 20120823-J(‰) | 20120829-J(‰) |
1号(10目) | 32.98 | — |
2号(24目) | 7.58 | — |
3号(50目) | 5.57 | — |
4号(65目) | 1.09 | — |
5号(80目) | 0.13 | — |
6号(100目) | 0.49 | 0.05 |
7号(120目) | 0.11 | 0.43 |
8号(150目) | 0.28 | 6.32 |
8号筛下物% | 95.18% | 99.32% |
时间 | 流动相A(0.05%磷酸水溶液)(%) | 流动相B(乙腈)(%) |
0~1.6 | 93→82 | 7→18 |
1.6~1.8 | 82→79.2 | 18→20.8 |
1.8~6.1 | 79.2→75 | 20.8→25 |
6.1~8.0 | 75→65 | 25→35 |
8.0~8.5 | 65→10 | 35→10 |
8.5~10.5 | 10 | 90 |
10.5~11.0 | 10→93 | 90→7 |
11.0~12.0 | 93 | 7 |
组别 | 剂量 | 流速(μm/s) |
(g/kg) | 0h | 0.5h | 2h | 4h | |
正常组 | 588.0±43.6 | 573.6±33.5 | 552.6±45.1 | 588.4±31.3 | |
复方丹参滴丸 | 0.27 | 590.6±44.0 | 619.7±32.3* | 609.1±45.2 | 604.1±38.3 |
E-01提取物低 | 2 | 580.0±33.6 | 613.6±39.5* | 562.6±75.1 | 588.4±51.3 |
E-01提取物中 | 4 | 590.0±24.4 | 637.3±52.2* | 570.8±76.5 | 596.8±71.8 |
E-01提取物高 | 8 | 583.1±36.7 | 639.0±48.5* | 611.8±55.5* | 599.1±52.4 |
浸膏浓度(μg/ml) | 换成成生药浓度(μg/ml) | 死亡率(%) |
0 | 0 | 0 |
200 | 700 | 0 |
400 | 1400 | 0 |
600 | 2100 | 3.3 |
800 | 2800 | 33.3 |
1200 | 4200 | 100 |
2000 | 7000 | 100 |
实施例 | 堆密度g/ml | 比表面积m2/g | 粒径mm |
3 | 0.62 | 0.005 | 1.83 |
2 | 1.02 | 0.02 | 1.01 |
4 | 1.25 | 0.05 | 0.48 |
5 | 0.81 | 0.01 | 1.22 |
6 | 1.09 | 0.03 | 0.69 |
Claims (13)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410270961.4A CN104224727B (zh) | 2013-06-17 | 2014-06-16 | 一种中药微丸的制备方法 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310237560.4 | 2013-06-17 | ||
CN201310237560 | 2013-06-17 | ||
CN2013102375604 | 2013-06-17 | ||
CN201410270961.4A CN104224727B (zh) | 2013-06-17 | 2014-06-16 | 一种中药微丸的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104224727A CN104224727A (zh) | 2014-12-24 |
CN104224727B true CN104224727B (zh) | 2018-04-03 |
Family
ID=52214213
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310277101.9A Active CN104224726B (zh) | 2013-06-17 | 2013-07-03 | 一种中药微丸的制备方法 |
CN201410270961.4A Active CN104224727B (zh) | 2013-06-17 | 2014-06-16 | 一种中药微丸的制备方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310277101.9A Active CN104224726B (zh) | 2013-06-17 | 2013-07-03 | 一种中药微丸的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN104224726B (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104886579A (zh) * | 2015-06-17 | 2015-09-09 | 吉林人参研究院 | 一种红参微丸及制备方法 |
CN107823180B8 (zh) * | 2017-11-21 | 2021-07-16 | 河南泓医药业有限公司 | 一种含挥发油的单味药微丸的制备方法 |
CN107823155B (zh) * | 2017-11-21 | 2021-06-11 | 河南泓医药业有限公司 | 一种单味药微丸的制备方法 |
CN109925296B (zh) * | 2017-12-19 | 2021-09-07 | 四川济生堂药业有限公司 | 一种中药微丸的包衣方法 |
CN110420194A (zh) * | 2019-07-09 | 2019-11-08 | 上海真仁堂药业有限公司 | 一种浓缩丸制备工艺 |
CN111617088A (zh) * | 2020-07-13 | 2020-09-04 | 中国人民解放军北部战区总医院 | 一种治疗川崎病心肌损伤的药物组合物及其应用 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1596917A (zh) * | 2003-09-16 | 2005-03-23 | 成都尚科药业有限公司 | 复方丹参微丸制备方法 |
CN1692914A (zh) * | 2004-05-08 | 2005-11-09 | 成都康弘科技实业(集团)有限公司 | 一种治疗冠心病心绞痛的中药微丸及其制备方法 |
CN1853670A (zh) * | 2005-03-29 | 2006-11-01 | 贵阳云岩西创药物科技开发有限公司 | 冠心丹参微丸制剂及其制备方法 |
CN101091725A (zh) * | 2006-06-23 | 2007-12-26 | 天津天士力制药股份有限公司 | 一种中药颗粒及其制备方法 |
CN101439041A (zh) * | 2007-11-22 | 2009-05-27 | 天津天士力制药股份有限公司 | 一种含灯盏花素的中药颗粒及其制备方法 |
CN101439087A (zh) * | 2007-11-22 | 2009-05-27 | 天津天士力制药股份有限公司 | 一种含丹参提取物的中药颗粒及其制备方法 |
CN101596240A (zh) * | 2009-07-06 | 2009-12-09 | 沈阳亿灵医药科技有限公司 | 一种双丹微丸及其制备方法 |
CN101773546A (zh) * | 2010-03-02 | 2010-07-14 | 沈阳药科大学 | 丹参有效成分同步定位释药微丸及其制备方法 |
CN102114072A (zh) * | 2009-12-31 | 2011-07-06 | 丽珠医药集团股份有限公司 | 丹参提取物缓释微丸及其制备方法和用途 |
CN102133194A (zh) * | 2011-03-11 | 2011-07-27 | 中国药科大学 | 一种丹参酮ⅱa固体分散体微丸的制备方法及其应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0632741A (ja) * | 1992-07-15 | 1994-02-08 | Mitsubishi Petrochem Co Ltd | 魚類の細菌感染症の予防・治療剤およびその利用 |
CN102028746B (zh) * | 2009-09-29 | 2014-12-24 | 天津天士力现代中药资源有限公司 | 一种治疗冠心病的药物及提取 |
-
2013
- 2013-07-03 CN CN201310277101.9A patent/CN104224726B/zh active Active
-
2014
- 2014-06-16 CN CN201410270961.4A patent/CN104224727B/zh active Active
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1596917A (zh) * | 2003-09-16 | 2005-03-23 | 成都尚科药业有限公司 | 复方丹参微丸制备方法 |
CN1692914A (zh) * | 2004-05-08 | 2005-11-09 | 成都康弘科技实业(集团)有限公司 | 一种治疗冠心病心绞痛的中药微丸及其制备方法 |
CN1853670A (zh) * | 2005-03-29 | 2006-11-01 | 贵阳云岩西创药物科技开发有限公司 | 冠心丹参微丸制剂及其制备方法 |
CN101091725A (zh) * | 2006-06-23 | 2007-12-26 | 天津天士力制药股份有限公司 | 一种中药颗粒及其制备方法 |
CN101439041A (zh) * | 2007-11-22 | 2009-05-27 | 天津天士力制药股份有限公司 | 一种含灯盏花素的中药颗粒及其制备方法 |
CN101439087A (zh) * | 2007-11-22 | 2009-05-27 | 天津天士力制药股份有限公司 | 一种含丹参提取物的中药颗粒及其制备方法 |
CN101596240A (zh) * | 2009-07-06 | 2009-12-09 | 沈阳亿灵医药科技有限公司 | 一种双丹微丸及其制备方法 |
CN102114072A (zh) * | 2009-12-31 | 2011-07-06 | 丽珠医药集团股份有限公司 | 丹参提取物缓释微丸及其制备方法和用途 |
CN101773546A (zh) * | 2010-03-02 | 2010-07-14 | 沈阳药科大学 | 丹参有效成分同步定位释药微丸及其制备方法 |
CN102133194A (zh) * | 2011-03-11 | 2011-07-27 | 中国药科大学 | 一种丹参酮ⅱa固体分散体微丸的制备方法及其应用 |
Non-Patent Citations (1)
Title |
---|
离心造粒法制备复方丹参微丸;袁亮 等;《中国实验方剂学杂志》;20100531;第16卷(第5期);第11页左栏第1段,"1.2 试药","2.1 空白丸芯的制备","2.2 复方丹参微丸的制备",第11页"2.4 微丸处方和工艺因素研究" * |
Also Published As
Publication number | Publication date |
---|---|
CN104224726A (zh) | 2014-12-24 |
CN104224726B (zh) | 2018-04-03 |
CN104224727A (zh) | 2014-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104224727B (zh) | 一种中药微丸的制备方法 | |
CN102416139B (zh) | 一种用于治疗乳腺疾病的中药组合物 | |
JP2016539955A (ja) | 薬物組成物、及びその製造方法、並びに使用 | |
EP3011965B1 (en) | Salvia miltiorrhiza extract, micropellet formulation thereof, methods of preparing same, and uses thereof | |
CN101011533B (zh) | 一种治疗肾阳虚的中药组合物及其制备方法和质量控制方法 | |
CN1957999B (zh) | 一种中药组合物及其制备方法和检测方法 | |
CN106214656A (zh) | 一种复方甘草酸苷片的制备及质量控制检测方法 | |
CN105616960A (zh) | 一种具有抗贫血作用的中药组合物及其制备方法与用途 | |
CN102485226B (zh) | 一种复方青蒿素类哌喹微丸及其制备方法 | |
JP2007016053A (ja) | 抗悪性腫瘍剤 | |
CN111568883B (zh) | 动物药材掩味缓释颗粒的制备方法 | |
CN101940558A (zh) | (-)-表没食子儿茶素没食子酸酯丸剂组合物及其用途 | |
CN104127510A (zh) | 小儿热速清颗粒矫味组合物及其颗粒剂和制法 | |
CN101204509B (zh) | 一种中药软胶囊及其制备方法 | |
CN101249119B (zh) | 复方氨酚葡锌分散片及其制备方法 | |
CN1939413B (zh) | 一种复方北豆根药物组合物 | |
WO2019232783A1 (zh) | 大麻二酚组合物及其用途 | |
CN100473408C (zh) | 一种清热化痰的药物组合物及其制备方法和用途 | |
CN100391528C (zh) | 一种治疗小儿厌食的中药组合物及其制备和质量控制方法 | |
CN104784239B (zh) | 一种快速溶出的珍菊降压片及其制备工艺 | |
CN103690672B (zh) | 用于治疗妇女卵巢功能异常引起的功血的控释制剂及其制备方法 | |
CN107496370A (zh) | 一种枸橼酸西地那非片剂组合物及其制备方法 | |
CN103142597B (zh) | 一种吐根有效成分的组合物及其制备方法和应用 | |
CN102018940B (zh) | 一种具有催乳作用的组合物及其制备方法和应用 | |
CN102198209A (zh) | 一种舒筋活血胶囊及其制备工艺 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: 300410 Tianjin city Beichen District Huaihe road and road intersection Dingjiang tianzhijiao Park forensic Center for Intellectual Property Department Applicant after: Tasly Pharmaceutical Group Limited by Share Ltd Address before: 300410 Tianjin city Beichen District Huaihe road and road intersection Dingjiang tianzhijiao Park forensic Center for Intellectual Property Department Applicant before: Tasly Pharmaceutical Group Co., Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP02 | Change in the address of a patent holder | ||
CP02 | Change in the address of a patent holder |
Address after: 300410 2 East Road Puji River, Beichen District, Tianjin (Tsun Li modern Chinese medicine city) Patentee after: Tasly Pharmaceutical Group Limited by Share Ltd Address before: 300410 Tianjin Beichen District Huaihe road and Ting Jiang West Road intersection heaven proud of the park Legal Center Intellectual Property Department Patentee before: Tasly Pharmaceutical Group Limited by Share Ltd |